Dr Reddys Laboratories (RDY) Receivables (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Receivables for 18 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.

• Quarterly Receivables rose 1.98% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 1.98% YoY) and the FY2026 annual result came in at $1.1 billion, up 1.98% from the prior year.
• Receivables advanced to $1.1 billion in Q1 2026 per RDY's latest filing, from $1.1 billion in the prior quarter.
• Over the last five years, Receivables for RDY reached as high as $1.1 billion in Q1 2026 and fell as low as $880.0 million in Q1 2022.
• A 5-year average of $956.4 million and a median of $939.0 million in 2023 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables grew 29.6% — and 2023, when it grew 0.34%.
• Year by year, Receivables stood at $893.0 million in 2022, then climbed by 5.15% to $939.0 million in 2023, then rose by 2.56% to $963.0 million in 2024, then advanced by 9.87% to $1.1 billion in 2025, then climbed by 1.98% to $1.1 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $1.1 billion, $1.1 billion, and $963.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.